Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.
D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000097:blood*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D009069:Movement Disorders / Q000139:chemically induced* / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*
D006834:Hydrazines; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases